Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | RHOA | P61586 | 1/20 | 0.44 |
| ▸ | FASN | P49327 | 5/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 7/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13837954 | 0.89 | RHOA (0.46) | PDK1PDK2RHOAFASNCHRM1 | |
| SCHEMBL2224359 | 0.88 | PDK1 (0.49) | PDK1PDK2FASNCHRM1GRM5 | |
| SCHEMBL13838821 | 0.86 | CHRM1 (0.43) | PDK1PDK2RHOAFASNCHRM1 | |
| SCHEMBL13838115 | 0.85 | FASN (0.49) | PDK1PDK2RHOAFASNGRM5 | |
| SCHEMBL13838109 | 0.84 | GRM5 (0.46) | PDK1PDK2RHOACHRM1GRM5 | |
| SCHEMBL13838057 | 0.83 | RHOA (0.46) | PDK1PDK2RHOAFASNGRM5 | |
| SCHEMBL13838014 | 0.82 | RHOA (0.46) | PDK1PDK2RHOAFASNGRM5 | |
| SCHEMBL13837979 | 0.82 | CNR2 (0.52) | RHOAFASNGRM5 | |
| SCHEMBL13838118 | 0.81 | RHOA (0.42) | PDK1PDK2RHOAFASNGRM5 | |
| SCHEMBL13837888 | 0.80 | GRM5 (0.46) | RHOAFASNCHRM1GRM5HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | PDK1 2190/4885PDK2 1280/4885RHOA 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.